Plain English Summary
Background and study aims
Schizophrenia is a long-term mental health condition that causes a range of symptoms including hallucinations (seeing or hearing things that aren’t there), delusions (beliefs that are not based on reality) and changes in behaviour. One of the most disabling factors affecting the quality of life of people with schizophrenia is the development of a set of so-called negative symptoms comprising social withdrawal, self-neglect, loss of motivation and mild impairment of intelligence. Standard drug treatments are effective in reducing psychotic symptoms such as paranoid delusions and hearing voices, but they have little impact on negative symptoms. Two major studies have shown that a standard antibiotic and anti-inflammatory drug called minocycline commonly used in acne and other infections, reduces negative symptoms in schizophrenia. It was also found to lessen the weight gain that standard treatments usually cause. Other studies suggest that minocycline may also improve positive symptoms (such as hallucinations and delusions) in acute (sudden) episodes of illness. The aim of this study is to investigate whether minocycline is especially effective given early in the course of illness and to understand how it works.
Who can participate?
Schizophrenic adults aged between 16 and 35 who are having an acute episode.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group are given 300mg of minocycline to take every day for 12 months. Those in the second group are given an identical looking placebo (dummy pill) to take every day for 12 months. During the study, all participants continue to receive their usual treatment. At the start of the study and then again after 2, 6, 9 12 and 15 months, participants complete a number of questionnaires to assess their symptoms. In addition at the start of the study and after 12 months, participants have a brain scan in order to find out if treatment with the study drug has caused any changes to their brain. Blood samples are also taken at the start of the study and then again after 6, 12 and 15 months to measure levels of chemicals called cytokines in the blood, which should show whether minocycline is working by blocking inflammation in the brain.
What are the possible benefits and risks of participating?
Minocycline is antibiotic that has been widely used for 50 years, for example in treating acne. The direct benefits of participating are additional clinical contacts and assessments plus any therapeutic effects of minocycline. The main side effect is that small patches of skin pigmentation may occur after several months of use, although this usually clears up if spotted early. Rare cases of liver damage have been reported at less than 1/10,000 cases. There is a small risk of pain or bruising during blood tests.
Where is the study run from?
Manchester Mental Health Social Care NHS Trust (lead site) and other mental health services in England and Scotland (UK)
When is the study starting and how long is it expected to run for?
July 2011 to June 2016
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Professor Bill Deakin
bill.deakin@manchester.ac.uk
Trial website
Contact information
Type
Scientific
Primary contact
Prof Bill Deakin
ORCID ID
http://orcid.org/0000-0002-2750-962X
Contact details
G907 Stopford Bldg
University of Manchester
Oxford Road
Manchester
M13 9PT
United Kingdom
Additional identifiers
EudraCT number
2010-022463-35
ClinicalTrials.gov number
Protocol/serial number
10411
Study information
Scientific title
The benefit of minocycline on negative symptoms in schizophrenia: Extent and mechanisms
Acronym
Study hypothesis
Primary efficacy predictions:
1. Minocycline minimises later negative symptoms when administered during the acute phase of early psychosis
2. Minocycline reduces or prevents the negative symptoms of schizophrenia by:
2.1. Reducing the loss of grey matter associated with early psychosis
2.2. Interfering with inflammatory cytokine production
2.3. An action on glutamate systems to improve negative symptoms and cognitive function
Mechanistic hypotheses:
1. Minocycline works by lessening a degenerative process, which is most active in the acute phase of psychosis and is responsible for the development of negative symptoms. The hypothesis predicts that the loss of grey matter, known to occur during the early years following onset of psychosis, will be lessened by minocycline treatment and that this will correlate with and explain improved negative symptoms.
2. Minocycline works by lessening an inflammatory process in the brain which gives rise to negative symptoms, possibly but not necessarily mediated by subtle neurodegeneration (see H1 above). The hypothesis predicts that circulating pro-inflammatory cytokines will be lessened by minocycline treatment.
3. Minocycline works by reversing defective NMDA glutamate receptor function to improve negative symptoms and frontal executive cognition. The hypothesis predicts that minocycline will improve functional brain imaging and performance measures of cognitive function. It also predicts that benefits on negative symptoms wane when the drug is stopped. However, it is possible glutamate actions could also be neuroprotective (see H1 above) whether or not it enhances glutamate function in the short-term.
Ethics approval
North West - Greater Manchester Central Research Ethics Committee, 06/07/2011, ref: 11/NW0218
Study design
Randomised; Interventional; Design type: Treatment, Drug
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Specialty: Mental Health, Primary sub-specialty: Psychosis
Intervention
Participants are randomised to one of two groups according to a randomised permuted blocks algorithm, after stratification by centre, as specified by the trial statistician.
Intervention group: Participants take 300mg daily minocycline for 12 months
Control group: Participants take a matched placebo daily for 12 months
Both groups continue treatment as usual from their clinical teams throughout the study period.
Follow up for all participants involves assessments at 2, 6, 9 and 12 months after randomization. All primary and secondary outcome assessments are carried out at randomization and 12 months. At 6 and 9 months all non-imaging outcome assessments are carried out and again at 15 months (3 months after stopping trial medication). The final assessments are at 15 months.
Intervention type
Drug
Phase
Not Applicable
Drug names
Minocycline
Primary outcome measure
Negative symptom severity is measured using the negative syndrome subscale score on the Positive and Negative Syndrome Scale (PANSS) at 2, 6, 9, 12 and 15 months
Primary mechanistic biomarker outcomes:
1. Medial prefrontal grey matter volume is measured using voxel-based morphometry at baseline and 12 months
2. Circulating IL6 cytokine concentrations are measured using Luminex arrays at baseline, 6, 12 and 15 months
3. Working memory performance and brain activation are measured using the n-back task during functional magnetic resonance imaging at baseline and 12 months
Secondary outcome measures
1. Body weight is measured using digital weighing scales at baseline and 12 months
2. Body mass index (BMI) is calculated using weight and height measurements taken at baseline and 12 months
3. General functional outcome is measured using the Global Assessment of Function (GAF) from DSMIV at baseline, 2, 6, 9, 12 and 15 months
4. Social and occupational functioning is measured using the Social Functioning Scale (SFS) self-rating in 7 domains at baseline, 6, 12 and 15 months
5. IQ is measured using the Blyler WAISIII short form at baseline, 12 and 15 months
6. Processing speed is measured using the Digit-symbol test at baseline, 12 and 15 months
7. Verbal fluency is measured using the FAS task at baseline, 12 and 15 months
8. Verbal learning is assessed using the Auditory Verbal Learning Task at baseline, 12 and 15 months
Secondary mechanistic biomarker outcomes:
1. Total and other regional grey matter volumes are measured using voxel-based morphometry at baseline and 12 months
2. Cytokine levels are measured using Luminex arrays at baseline, 6, 12 and 15 months
3. Resting connectivity and distribution of the Hurst exponent is assessed using functional magnetic resonance imaging at baseline and 12 months
Overall trial start date
01/07/2011
Overall trial end date
09/06/2016
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Male or female aged 16-35 years
2. Current DSM-IV diagnosis of schizophrenia, schizophreniform or schizoaffective psychosis, psychosis NOS as assessed with the clinical team
3. In an episode as defined by
3.1. An onset or exacerbation of symptoms
3.2. With continuing positive symptoms scoring at least mild (>2) on items P1, P2 or P6 of the PANSS within the last month
4. In contact with early intervention, community or inpatient services
5. Within 3 years of onset of symptoms
6. Current IQ greater than 70
7. Female patients must use effective birth control with a negative pregnancy test
8. Able to understand and willing to give written informed consent
9. Fluent in English
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 170; UK Sample Size: 170
Participant exclusion criteria
1. Current substance misuse diagnosis that in the opinion of the investigator may interfere with the study (urine toxicology screens will be used to monitor drug use)
2. Patients who, in the Investigator’s judgment pose a current serious suicidal or violence risk
3. Prior tetracycline use within 2 months of baseline visit or history of sensitivity or intolerance
4. History of systemic lupus erythematosis (SLE) or a history of SLE in a first-degree relative
5. Use of any investigational drug within 30 days of baseline visit
6. Relevant current or past haematologic, hepatic, renal, neurological or other medical disorder that in the opinion of the investigator may interfere with the study
7. Clinically significant deviation from the reference range in clinical laboratory test results as judged by the Investigator
8. Previous randomisation in the present study
9. Pregnant or nursing
Recruitment start date
10/12/2012
Recruitment end date
01/05/2015
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Manchester Mental Health Social Care NHS Trust
NHS R&D Office
Rawnsley Bldg
Manchester Royal Infirmary
Hathersage Road
Manchester
M13 9WL
United Kingdom
Trial participating centre
Greater Manchester West MH NHS Foundation Trust
NHS R&D Office
Harrop House
Bury New Road
Manchester
M25 3BL
United Kingdom
Trial participating centre
Camden And Islington NHS Foundation Trust
R&D Office
St Pancras Hospital
4 St Pancras Way
London
NW1 0PE
United Kingdom
Trial participating centre
North West London Mental Health
London West Mental Health R&D Consortium
Uxbridge Road
London
UB1 3EU
United Kingdom
Trial participating centre
West London Mental Health NHS Trust
Research and Development Directorate
Uxbridge Road
London
UB1 3EU
United Kingdom
Trial participating centre
South London And Maudsley NHS Foundation Trust
NHSSLaM/IoP R&D Office
De Crespigny Park
London
SE5 8AF
United Kingdom
Trial participating centre
Cambridgeshire and Peterborough NHS Foundation Trust
Research and Development Office
Fulbourn Hospital
Cambridge
CB21 5EF
United Kingdom
Trial participating centre
Lancashire Care NHS Foundation Trust
NHS R&D Office
Sceptre Way
Walton Summit
Preston
CB21 5EF
United Kingdom
Trial participating centre
Royal Edinburgh Hospital
NHS Lothian
NHSR&D office
Morningside Place
Edinburgh
EH10 5HF
United Kingdom
Trial participating centre
Lynebank Hospital
NHS Fife
NHS R&D Dept
Halbeath Rd
Dunfirmline
KY11 4UW
United Kingdom
Trial participating centre
NHS Forth Valley Royal
NHS R&D Dept
Stirling Road
Larbert
FK5 4WR
United Kingdom
Trial participating centre
Borders General Hospital
NHS Borders
NHS R&D Office
Melrose
TD6 9BS
United Kingdom
Trial participating centre
Salford NHS Foundation Trust
NHS R&D Office
Stott Lane
Salford
M6 8HD
United Kingdom
Trial participating centre
Barnet, Enfield and Haringey Mental Health Trust
Community Mental Health Services
305309 Fore Street
Edmonton
London
N9 0PD
United Kingdom
Trial participating centre
University of Cambridge
NHS Department of Psychiatry
Herchel Smith Building,
Robinson Way
Cambridge
CB2 0SZ
United Kingdom
Trial participating centre
University of Manchester
Neuroscience and Psychiatry Unit,
Dept of Psychiatry
Stopford Building
Oxford Road
Manchester
M13 9PL
United Kingdom
Trial participating centre
Kings College NHS
Institute of Psychiatry
Box P089
De Crespigny Park
London
SE5 8AF
United Kingdom
Trial participating centre
Birmingham And Solihull Mental Health NHS Foundation Trust
Unit 1
50 Summer Hill Road
Birmingham
B1 3RB
United Kingdom
Trial participating centre
University College London NHS Institute of Neurology
Queen Square
London
WC1N 3BG
United Kingdom
Trial participating centre
Cheshire And Wirral Partnership NHS Foundation Trust
Trust Board Offices
Upton Lea Resource Centre
The Countess Of Chester Health Park
Chester
CH2 1BQ
United Kingdom
Funders
Funder type
Government
Funder name
National Institute for Health Research
Alternative name(s)
NIHR
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Submission of main results for publication by December 2016
IPD Sharing plan:
The datasets generated during and/or analysed during the current study will be stored in a publically available repository not yet identified.
Intention to publish date
31/07/2017
Participant level data
Stored in repository
Basic results (scientific)
Publication list
2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30322824